# Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

> **NCT00616551** · PHASE3 · COMPLETED · sponsor: **Ambrilia Biopharma, Inc.** · enrollment: 65 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** C2L-OCT-01 PR, 30 mg
- **DRUG:** Octreotide acetate prolonged release, 30 mg

## Key facts

- **NCT ID:** NCT00616551
- **Lead sponsor:** Ambrilia Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2008-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00616551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00616551, "Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00616551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*